DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Uterine Fibroids Market: Industry Analysis & Outlook (2017-2025)" report to their offering.
Global Uterine Fibroids Drugs Market: Industry Analysis & Outlook (2017-2025) analyzes the development of this market, with focus on the US and European markets. The major trends, growth drivers, as well as issues being faced by the market are discussed in detail in this report.
The global uterine market has no direct indication-approved drug. Gonadotropin-releasing hormone analogues (GnRHa) agents are used to reduce size of tumors and reduce blood loss to correct anemia. With the launch of two potential drug candidates, Relugolix and Elagolix, the market will experience robust growth with higher penetration rate to treat women with this disease. The US will promulgate the introduction of these drugs and will be the largest market for uterine fibroids.
The global uterine fibroids drugs market is expected to experience robust growth post the launch of therapeutic drugs, primarily due to increasing patient base, rise in female population, and increasing healthcare expenditure. However, the market growth is hindered by high R&D costs and regulatory warnings.
The major trends of the market includes development of new drugs, increase in demand for minimal invasive surgeries, and expansion of new technologies. However, the market will be hindered by tough regulatory warnings and high R&D costs.
The four major players: AbbVie, Myovant Sciences, Astra Zeneca, and Neurocrine Biosciences are being profiled along with their key financials and strategies for growth. The report contains a comprehensive analysis of the global uterine fibroids market along with the study of the regional markets.
- Increasing Female Population Worldwide
- Rising Spending on Public Health Programs for Females
- Growing Uterine Fibroids Market in Emerging Economies
- Increased Spending on Medicines
- Increasing Global Healthcare Expenditure
Trends and Developments
- Development of New Drugs
- Increasing Demand for Minimally Invasive Surgeries
- Expansion of More Efficient and Advanced Technology
Issues and Challenges
- FDA's Black Box Warnings
- High R&D Costs
- Drug Progress Challenges in Developing Countries
- Myovant Sciences Ltd. (Roivant Sciences, Ltd.)
- Neurocrine Biosciences
For more information about this report visit http://www.researchandmarkets.com/research/7rdrqr/global_uterine